Market Closed -
Börse Stuttgart
07:03:09 02/07/2024 BST
|
5-day change
|
1st Jan Change
|
7
EUR
|
-1.41%
|
|
+6.77%
|
-12.88%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,240
|
578.9
|
264.8
|
501.9
|
507
|
-
|
-
|
Enterprise Value (EV)
1 |
1,240
|
578.9
|
264.8
|
266.8
|
507
|
507
|
507
|
P/E ratio
|
-10.1
x
|
-7.1
x
|
-2.62
x
|
-4.69
x
|
-4.37
x
|
-3.89
x
|
-3.69
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
36.6
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
36.6
x
|
EV / EBITDA
|
-16.9
x
|
-7.42
x
|
-2.92
x
|
-4.57
x
|
-4.26
x
|
-3.95
x
|
-4.68
x
|
EV / FCF
|
-27
x
|
-9.57
x
|
-3.43
x
|
-5.8
x
|
-16.9
x
|
-5.17
x
|
-3.4
x
|
FCF Yield
|
-3.7%
|
-10.4%
|
-29.2%
|
-17.2%
|
-5.92%
|
-19.3%
|
-29.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
36,634
|
39,382
|
44,953
|
54,552
|
67,422
|
-
|
-
|
Reference price
2 |
33.85
|
14.70
|
5.890
|
9.200
|
7.520
|
7.520
|
7.520
|
Announcement Date
|
23/03/21
|
21/03/22
|
16/03/23
|
11/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
13.86
|
EBITDA
1 |
-
|
-73.22
|
-77.97
|
-90.8
|
-109.7
|
-119
|
-128.3
|
-108.4
|
EBIT
1 |
-28.57
|
-74.19
|
-78.87
|
-91.77
|
-110.8
|
-124.1
|
-144.7
|
-159
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,147.41%
|
Earnings before Tax (EBT)
1 |
-
|
-73.7
|
-78.72
|
-89.12
|
-100.7
|
-114.2
|
-137.7
|
-151.7
|
Net income
1 |
-
|
-73.7
|
-78.72
|
-89.12
|
-100.7
|
-114.2
|
-137.7
|
-151.7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,094.48%
|
EPS
2 |
-
|
-3.360
|
-2.070
|
-2.250
|
-1.960
|
-1.721
|
-1.931
|
-2.036
|
Free Cash Flow
1 |
-
|
-45.94
|
-60.48
|
-77.22
|
-86.54
|
-30
|
-98
|
-149
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,075.06%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/02/20
|
23/03/21
|
21/03/22
|
16/03/23
|
11/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-21.87
|
-25.42
|
-24.73
|
-28.42
|
-31.16
|
-28.73
|
-29.25
|
-30.05
|
-30.85
|
-
|
-
|
EBIT
1 |
-22.8
|
-23.26
|
-20.7
|
-25.69
|
-22.12
|
-25.68
|
-24.99
|
-28.68
|
-31.43
|
-28.99
|
-30.21
|
-31.78
|
-33.12
|
-33.66
|
-34.48
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-22.77
|
-23.16
|
-20.29
|
-24.83
|
-20.85
|
-23.94
|
-22.94
|
-25.48
|
-28.33
|
-25.01
|
-28.02
|
-29.8
|
-31.25
|
-32.22
|
-33.18
|
Net income
1 |
-22.77
|
-23.16
|
-20.29
|
-24.83
|
-20.85
|
-23.94
|
-22.94
|
-25.48
|
-28.33
|
-25.01
|
-28.02
|
-29.8
|
-31.25
|
-32.22
|
-33.18
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.5800
|
-0.5900
|
-0.5100
|
-0.6300
|
-0.5200
|
-0.5300
|
-0.5000
|
-0.4400
|
-0.4900
|
-0.3700
|
-0.4124
|
-0.4353
|
-0.4582
|
-0.4800
|
-0.4933
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/03/22
|
09/05/22
|
11/08/22
|
07/11/22
|
16/03/23
|
08/05/23
|
10/08/23
|
06/11/23
|
11/03/24
|
06/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
235
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-45.9
|
-60.5
|
-77.2
|
-86.5
|
-30
|
-98
|
-149
|
ROE (net income / shareholders' equity)
|
-39%
|
-28%
|
-36%
|
-45.1%
|
-45.7%
|
-38.7%
|
-34.2%
|
ROA (Net income/ Total Assets)
|
-37.5%
|
-26.3%
|
-32.7%
|
-40.3%
|
-37.9%
|
-32.5%
|
-
|
Assets
1 |
196.5
|
298.8
|
272.9
|
249.6
|
301.2
|
423.6
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.67
|
0.94
|
2.08
|
0.85
|
-
|
0.5
|
1
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
7.22%
|
Announcement Date
|
23/03/21
|
21/03/22
|
16/03/23
|
11/03/24
|
-
|
-
|
-
|
Last Close Price
7.52
USD Average target price
19
USD Spread / Average Target +152.66% Consensus |
1st Jan change
|
Capi.
|
---|
| +16.44% | 122B | | +18.94% | 114B | | +19.62% | 25.71B | | -25.37% | 19.02B | | -20.21% | 15.83B | | -20.20% | 15.32B | | -47.37% | 14.88B | | +59.91% | 14.82B | | +4.35% | 14.1B |
Bio Therapeutic Drugs
|